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ABSTRACT 
Chronic non-healing skin wounds, such as leg ulcers and pressure sores, represent a 
major clinical problem and a financial burden for the health care systems. Chronic 
wounds are characterised by prolonged inflammatory phase that results in high levels of 
elastase, reactive oxygen species (ROS) and diminished growth factor activity. Under 
normal physiological conditions, elastase is a powerful host defence and its activity is 
regulated by endogenous inhibitors. The unrestrained elastase activity in chronic 
wounds may be tuned by exogenous active materials that inhibit elastase. Secretory 
leucocyte protease inhibitor, SLPI, is a potent endogenous inhibitor of elastase. Peptide 
fragments, KRCCPDTCGIKCL (Pep4) and KRMMPDTMGIKML (Pep4M), selected 
from SLPI primary structure were studied as potential elastase inhibitors. Kinetic 
studies performed for human neutrophil elastase (HNE) and porcine pancreatic elastase 
(PPE) in presence of these peptides revealed that both behave as uncompetitive and 
non-competitive inhibitors of HNE and PPE, respectively. The influence of ROS and 
albumin on Pep4 and Pep4M inhibitory activity towards elastase, reveals that this 
mixture increases the inhibitory activity of both peptides. These peptides were 
incorporated in hyaluronic acid hydrogels, to evaluate the possibility of being used as 
active compounds in a drug delivery system. Assessment of HNE and PPE activity in 
the presence of these hydrogels formulations revealed a considerable decrease in 
enzyme activity. Although, only moderated elastase inhibition was observed, these 
peptides represent potential candidates for chronic wound applications, as there is no 
need for complete elastase inhibition in the normal wound healing process. 
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reactive nitrogen species; Pep4, Peptide 4; Peptide 4, KRCCPDTCGIKCL; Pep4M, Peptide 4 Modified; 
Peptide 4 Modified, KRMMPDTMGIKML; p-NA, p-Nitroaniline; DTT, DL-Dithiothreitol. 
 
INTRODUCTION 
Wound healing is a complex biological process that ultimately results in restoration of 
tissue integrity 1. This complex cascade of events starts from the moment of injury and 
continues for varying periods of time depending on the severity of the wounding 2. 
Physiologically, this process can be categorized in three different phases: inflammatory 
(consisting of the establishment of homeostasis and inflammation); proliferative 
(consisting of granulation, contraction and epithelialization) and remodelling (that 
ultimately determines the strength and appearance of the healed tissue) 2-6. However, 
wound healing is not always a linear process and it can progress forward and backward 
through the different phases, depending on various intrinsic and extrinsic factors 3. 
Normal wound healing is a carefully controlled balance of destructive processes 
necessary to remove damaged tissue and repair processes which lead to new tissue 
formation 7. Chronic non-healing wounds, such as pressure sores, diabetic foot ulcers, 
venous leg ulcers and other delayed wounds, have failed the progress through the 
normal stages of healing and therefore enter in a state of pathologic inflammation 7, 8.  
Exudates from chronic non-healing wounds contain elevated levels of proteolytic 
enzymes like elastase 9, matrix metalloproteinase (MMP) 10 and plasmin 11, 12, reactive 
oxygen species (ROS) 7, 9, 13 and reactive nitrogen species (RNS) 13. The excessive 
production of elastase and other proteolytic enzymes by polymorphonuclear 
granulocytes leads to considerable reduction on the amounts of growth factors and 
proteinase inhibitors, resulting in an imbalance between degradation and remodelling 
processes 13. In addition, the overproduction of ROS (such as, hydrogen peroxide 
(H2O2), hypochlorous acid (HOCl), hydroxyl radicals (HO•), superoxide anions (O2•–)) 
and RNS species (like nitric oxide (NO) and its peroxynitrite derivatives) results in an 
imbalance oxidant/antioxidant status in chronic wounds 13. ROS and RNS play an 
important role in the normal wound healing process by killing invading microorganisms 
and therefore their presence is necessary in the early stages of wound healing to initiate 
the inflammatory response 7, 13, 14. At low concentrations (0.01-1 µM) oxidizing species 
such as hydrogen peroxide (H2O2) have been shown to have a positive effect in acute 
wound repair, stimulating fibroblast proliferation 7. However, their continuous presence 
is thought to be detrimental to the healing process 15. Studies have shown that reactive 
oxygen species can induce matrix metalloproteinase production and in severe cases can 
result in tissue necrosis and permanent tissue damage 7, 13. Therefore, decreasing the 
levels of ROS/RNS species and elastase in the wound fluid seems a suitable way to 
release the wound from the inflammatory phase and thus progress the normal wound 
healing process. 
Currently, most of the dressings have been designed to create a moist wound healing 
environment, which allows the wound fluids and growth factors to remain in contact 
with wound and thus accelerating wound healing 16. In most of the cases, these 
dressings are based on polymeric hydrogels, which are three-dimensional networks that 
swell quickly by imbibing a large amount of water. These materials closely resemble 
the living tissues because of their high water contents, soft and rubbery consistency and 
their biocompatibility to tissue and blood 16. Hydrogels are prepared from synthetic and 
natural polymers. Hyaluronic acid (HA) is a naturally occurring polymer associated 
with various cellular processes involved in wound healing 17. The physiological activity 
of hyaluronic acid (HA) polymers and oligomers makes it a promising and ideal 
material for wound dressing applications. HA can be tailored to a specific application 
but still retains its natural biocompatibility, biodegradability and lack of 
immunogenicity 18. 
In a previous work 19, we have reported the application of an on-off switch, based on the 
reversible process of phosphorylation/dephosphorylation, to control the inhibitory 
activity of small peptides towards elastase, in wound dressing applications. These 
peptides were selected from the antimicrobial domain of an endogenous elastase 
inhibitor, secretory leucocyte protease inhibitor (SLPI). These tridecamer peptides, Pep4 
(KRCCPDTCGIKCL) and Pep4M (KRMMPDTMGIKML), revealed differential 
elastase inhibitory activity for the non-phosphorylated (high inhibition) and 
phosphorylated (low inhibition) form. The biomatrices 20, 21 proposed to enclose this 
system were protease degradable materials. The biomatrix disruption was triggered by 
wound medium elastase, followed by active material release (inhibitor-peptides) and 
then in a later stage protein kinase release. The protein kinase promotes the inhibitors 
phosphorylation and subsequence reduction on peptides inhibitory activity towards 
elastase. This approach although promising required the control of several variables, 
such as ATP levels at wound site, peptides and protein kinase loadings and degradation 
rates, biomatrix degradation rate, among others. 
In this article, an alternative wound dressing system is proposed. A model drug delivery 
system, based in hyaluronic acid hydrogels (HA), has been used to test the applicability 
of these 13-mer peptides, Pep4 and Pep4M, in wound dressing applications. In addition, 
a complete study of the kinetic parameters obtained for the substrate hydrolysis by PPE 
and HNE in presence of both peptides, is also reported herein. Lastly, it is evaluated the 
effect of the ROS, that are present in high concentrations in chronic non-healing 
wounds, on the inhibitory activity of the studied peptides towards PPE.  
 
MATERIALS AND METHODS 
Reagents 
The inhibitor-peptides KRCCPDTCGIKCL (Pep4) and KRMMPDTMGIKML (Pep4M) 
were tailor-made by JPT Peptide Technologies GmbH (Berlin, DE) and the non-peptide 
inhibitor, elastatinal (BML-PI103) was obtained from Enzo Life Sciences (Farmingdale, 
NY, US). Porcine pancreatic elastase (E1259) and the chromogenic substrate N-
Succinyl-(Ala)3-p-nitroanilide (S4760), were purchased from Sigma Chemical Co (St. 
Louis, MO, US). Human neutrophil elastase (324681) and the colorimetric substrate 
MeO-Succinyl-(Ala)2-Pro-Val-p-nitroanilide (324696) were obtained from Calbiochem 
(Darmstadt, DE). Reactive oxygen species (ROS) were prepared using hydrogen 
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peroxide (30% (w/v), 121076) from Panreac (Barcelona, ES), sodium nitrite (10256) 
from BDH (Poole Dorset, UK), manganese dioxide (105957) from Merck (Darmstadt, 
DE), sodium hypochlorite solution (42,504-4), xanthine (X0626), xanthine oxidase 
(X4500) and cytochrome c, from bovine heart (C2037) from Sigma Chemical Co (St. 
Louis, MO, US). Albumin from bovine serum (A3983) used in the ROS assays was also 
supplied by Sigma Chemical Co (St Louis, MO, US). Hyaluronic acid (1.7 million 
Daltons) supplied from Contipro C a. s. (Dolní Dobrouč, CZ), was used in the hydrogels 
formulations. 
All reagents were acquired with analytical grade and used as supplied. The aqueous 
solutions were prepared in deionized water and stored at 4ºC. 
The inhibition kinetic assays were performed in microplate format, using 96 wells 
microplates (F96) from Nunc (Rochester, NY, US). 
The ROS and HA hydrogel assays were performed in one milliliter quartz cells (108-
000-10-40) from Hellma (Müllheim, DE). 
The reagents used in the electrophoresis (SDS-PAGE) assay, acrylamide/bisacrylamide 
solution (37.5:1) at 40% (161-0148), N,N,N´,N´-tetra-methyl-ethylenediamine 
(TEMED, 161-0800), ammonium persulfate (APS, 161-0700) and broad range protein 
marker (Precision Plus Protein Standards, 161-0373) were purchased to Bio-Rad 
Laboratories (Hercules, CA, US). 
 
Elastase Inhibition Kinetics 
Inhibition kinetics for the synthetic peptides (Pep4 and Pep4M) and elastatinal were 
determined using N-succinyl-Ala3-p-nitroanilide as PPE substrate, in 100 µM Tris/HCl, 
pH 8.0 and MeO-Succinyl-Ala2-Pro-Val-p-nitroanilide as HNE substrate, in 200 µM 
Phosphate Buffer, pH 8.0 22. The assays were carried out at room temperature, during 
30 minutes, in 96 wells microplates (F96, Nunc, Rochester, NY, US) and monitored at 
410 nm, using a UV-Vis Varian, Cary 50 reader (Palo Alto, CA, US). 
Briefly, an elastase solution (15 µL) preincubated (for five minutes) with the inhibitor 
solution (15 µL) was added to a total assay mixture containing buffer and substrate (270 
µL). Nine different substrate concentrations between 0.1 and 3.0 mM were used for PPE 
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(0.3 units/mL) and between 0.1 and 2.5 mM for HNE (0.5 units/mL). Inhibitors 
concentration used in the current assays ranged between 1 and 64 µM. These assays 
were all performed in triplicate and represented as mean ± SD. 
Initial rate data was fitted to Michaelis-Menten equation using a non-linear regression 
analysis (OriginPro 8.5 Software) and also fitted to a Direct Linear Plot (Hyper32.exe, 
Version 1.0.0, 2003). 
Preceding these enzymatic assays, enzyme and inhibitor incubation times were 
determined performing kinetic assays using a constant concentration of inhibitor and 
incubation periods of 5, 15 and 30 minutes. The obtained hyperbolic curves were 
superimposed and therefore the lowest incubation time (5 minutes) was employed for 
all the inhibitors tested herein. 
Prior to the kinetic assays, the microplate well pathlength (l=0.82 cm) was determined 
using p-nitroaniline solutions ranging from 20 to 100 µM, in a total volume of 300 µL 
and using 8.8 mM−1cm−1 as the molar extinction coefficient of p-nitroaniline at 410 nm 
23-25. 
The microplates used in the current assays were blocked with albumin solution (BSA, 1 
mg/mL) overnight, followed by three washes of thirty minutes with buffer (Tris/HCl or 
Phosphate buffer, pH 8.0). This pretreatment with BSA was applied to the microplates 
to avoid UV radiation absorption by the microplate material. 
 
Effect of ROS on Elastase Activity - In Vitro Study 
Preparation of Reactive Oxygen Species (ROS). The influence of reactive oxygen 
species (hydrogen peroxide (H2O2), hypochlorous acid (HClO), peroxynitrite (ONOO-) 
and superoxide (O2•-)) on the inhibitor-peptides activity towards elastase was evaluated 
using normal physiological levels of these species (100 mM, 100 µM, 500 µM and 400 
µM, respectively,) 26. The preparation of these reactive oxygen species (ROS) was 
performed as described herein. 
Hypochlorous acid was prepared immediately before use by adding diluted sulphuric 
acid to sodium hypochlorite till pH 6.2 is reached (Eq. 1) 27-29. The concentration of 
HClO used was 100 µM, which was determined from its molar absorptivity of 100 M-
1cm-1 at 235 nm 26, 30, 31. 𝑂𝐶𝑙!   + 𝐻!   ↔ 𝐻𝑂𝐶𝑙          (1) 
Peroxynitrite was obtained as previously reported by Hughes and co-workers 32. Briefly, 
100 mL of ice-cold hydrochloric acid (0.6M)/hydrogen peroxide (0.7M) solution was 
poured into a stirred iced solution of sodium nitrite (0.6 M, 100mL) followed 
immediately by sodium hydroxide (1.5 mM, 100 mL) (Eq. 2). To increase the 
peroxynitrite yield in the reaction, all the solutions were mixed as fast as possible. The 
excess of hydrogen peroxide, used to minimize nitrite contamination, was removed 
from the peroxynitrite solution by adding manganese dioxide (6 mg/mL) and keeping 
the solution at 4ºC for 30 minutes 33. The solution was then filtered in cellulose filters 
(three times) and then in nylon membrane filters with pore size of 0.2 µM (one time). 
The obtained solution was then frozen at -20ºC overnight, resulting in the formation of a 
top yellow layer due to freeze fractionation of peroxinitrite. This yellow top layer was 
scraped and stored at -20ºC, for further studies. The concentration of peroxynitrite was 
determined by measuring its absorbance at 302 nm in 1M sodium hydroxide (Ɛ=1670 
M-1cm-1) 32, 34-37. 𝐻!𝑂! +   𝑁𝑂!!   →   𝑂𝑁𝑂𝑂!   +   𝐻!𝑂          (2)   
The superoxide was generated from the reaction of xanthine oxidase with xanthine 26, 38, 
39. Briefly, 1.05 units of xanthine oxidase were added directly to 23 mL of 2.1 mM 
xanthine solution, previously prepared in PBS buffer, pH 7.0. The enzymatic reaction 
was carried out for 1 hour at 37ºC in a 25 mL conical flask with stirring. The 
concentration of O2•- was determined by observing the reduction of cytochrome c (0.8 
mM) at 550 nm, using an absorption coefficient of 2.1x104 M-1cm-1 40, 41. 
 
Assessment of Elastase Activity in presence of ROS. Prior to elastase activity assay, the 
inhibitors (20 µM Pep4, Pe4M and elastatinal) were incubated with each oxidant and 
oxidant plus albumin (50 mg/mL of BSA), in equal proportions (volumes), at room 
temperature, for two hours 26 27. Afterwards, these solutions were incubated with 
elastase for five minutes at room temperature, immediately before initiating the enzyme 
activity assay. 
Porcine Pancreatic Elastase activity was assayed spectrophotometrically by 
continuously measuring the rate of hydrolysis of the substrate N-succinyl-Ala-Ala-Ala-
p-nitroanilide to p-nitroaniline, at 410 nm 42. Briefly, the reaction was initiated by the 
addiction of PPE (0.3 units/mL, 33.3 µL) to a buffer solution (100 µM Tris/HCl, pH 8.0, 
933.3 µL) containing substrate (4.4 mM, 66.7 µL). Inhibitor experiments with and 
without oxidant treatment were performed under identical conditions. The reaction was 
carried out at room temperature, during 60 minutes, in a one mL quartz cell (108-000-
10-40, Hellma, Müllheim, DE) and monitored at 410 nm using an UV-Vis Shimadzu 
spectrophotometer (UV-2501PC, Kyoto, JP).  
 
Study of the Reaction BSA-H2O2 by Electrophoresis (SDS-PAGE). SDS-PAGE 
electrophoresis was used to follow the reaction between albumin (BSA) and hydrogen 
peroxide (H2O2) and this assay was performed as described by Laemmli 43. This 
reaction occurs in ROS assay, in which high concentrations of albumin and hydrogen 
peroxide were applied comparatively to what will be used herein. In this assay lower 
BSA (1.125 to 2.0 mg/mL) and H2O2 (0.25 to 4.0 mg/mL) concentrations were 
employed, although the initial proportion between both components was kept. The 
reaction mixtures were incubated during two and twenty-two hours at room 
temperature. Diluted samples of BSA, BSA + H2O2 oxidant mixture and protein 
markers were loaded into 4% stacking gel and further separated in 8 and 10% resolving 
gel, under denaturing conditions. The gels were stained with Coomassie blue R-250 
overnight and destained with methanol/acetic acid (40/7% and 5/7%) solutions. 
 
Elastase Activity Assay in the presence of HA Hydrogel Formulations 
Hydrogel Preparation. The hydrogel crosslinking procedure used herein has been 
previously outlined by J. W. Burns and co-workers 44. Briefly, in order to obtain an 
autocrosslinked hyalorinic acid (HA) hydrogel 45, 100 mg of HA was dissolved in 10 
mL of deionized water. The pH of the aqueous solution was adjusted to 4.7, using HCl 
1M and then casted into 35 mm diameter petri dishes (83.1800.002, Sarstedt, DE). 
Subsequently, the petri dishes were frozen at -20ºC for 2.5 days and then thawed at 
25ºC. Afterwards, the hydrogels were dehydrated in an incubator shaker (Infors HT – 
Minitron, Bottmingen, CH) at 35ºC during approximately 10 hours. Then the thickness 
of the obtained films (Figure 1) was determined using a digital micrometer (series 293, 
Mitutoyo, Kanagawa, JP).  
 
Water Content and Thickness of HA Hydrogels. To determine the water content, the 
dehydrated HA hydrogels were weighed and then incubated in 4 mL of deionized water 
for 30 minutes. The water excess was removed and the hydrogels re-weighed. The water 
content of the hydrogels was calculated according to equation 3 
%  𝑊𝑎𝑡𝑒𝑟 =   𝑊ℎ −𝑊𝑑𝑊ℎ 𝑥100          (3) 
where, Wh represents the weight of the hydrated hydrogel and Wd the weight of the 
dried film. The thickness of the HA films was determined using a digital micrometer 
(series 293, Mitutoyo, Kanagawa, JP). All measurements performed in this section were 
made in triplicate. 
 
Elastase Activity Assay in HA Hydrogels. The dried HA films prepared in two sections 
before (Figure 1), were submerged in 2 mL of inhibitor solutions (Pep4, Pep4M or 
elastatinal), prepared in 200 µM phosphate buffer, pH 8.0. The inhibitor concentrations 
selected to hydrate the HA films were those that highly inhibits elastase in the kinetic 
assays. Therefore 1, 4 and 64 µM concentrations of Pep4, Pep4M and elastatinal 19 were 
used in the PPE assay and 32, 1 and 64 µM concentrations in HNE assays, respectively. 
HA hydrogels were also hydrated with 2 mL of 200 µM phosphate buffer, pH 8.0, to 
use as control in the elastase enzymatic assay. These hydrogels, with a final pH of 8.0, 
were allowed to incubate for 30 minutes at room temperature.  
PPE and HNE activity was assayed spectrophotometrically using N-succinyl-Ala-Ala-
Ala-p-nitroanilide and MeOSuccynyl-Ala-Ala-Pro-Val-p-nitroanilide as respective 
substrates. Briefly, the HA hydrated hydrogels (described in this section) were 
incubated in 1mL of elastase solution (36 munits/mL of PPE and HNE) 46 for 1 hour at 
room temperature 46-49. The elastase supernatant (933.3 µL) from each hydrogel was 
assayed with the respective substrate (66.7 µL of N-Suc-Ala3-p-NA (4.4 mM) and 
MeOSuc-Ala2-Pro-Val-p-NA (3.0 mM)), for five minutes at room temperature. The 
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spectrophotometric measurement of the release of p-nitroaniline from the enzymatic 
hydrolysis of the substrates was performed at 410 nm in a Shimadzu spectrophotometer 
(UV-2501PC, Kyoto, Japan) using one mL quartz cuvettes (Hellma, Müllheim, DE). 
 
RESULTS AND DISCUSSION 
The tridecamer peptide Pep4 primary structure, KRCCPDTCGIKCL (Figure 2), was 
selected from the natural human neutrophil elastase (HNE) inhibitor, secretory 
leucocyte protease inhibitor (SLPI). This peptide structure was picked from the inner 
part of an extended planar spiral in the N-terminal domain of SLPI 50. Due to the high 
cysteine content of this tridecamer peptide, a mutation of this peptide was also designed 
having replaced the cysteine residues for a less reactive residue, methionine, and 
therefore generating a second 13-mer peptide Pep4M, KRMMPDTMGIKML. 
 
Elastase Inhibitor Kinetic Assays  
Enzymatic kinetics of PPE and HNE were studied in the presence of the inhibitor-
peptides (Pep4 and Pep4M) and elastatinal (non-peptidic elastase inhibitor used as 
control) 51-53. Kinetic data shown in Michaelis-Menten plots for Pep4 (Figure 3 a) and 
c)) reveal a good fit of the experimental data to a hyperbole. No relevant differences 
have been observed in data analysed using Michaelis-Menten plot and the direct linear 
plot (data not shown). Michaelis-Menten plot for PPE and HNE in presence of Pep4 
(Figure 3 a) and c)), reveals no linear relationship between the inhibitor concentration 
and the resulting kinetic parameters, 𝐾!!"" and 𝑉!"#!"" (see Table I). However, there is a 
general tendency within the obtained values of 𝐾!!"" and 𝑉!"#!"" for the different inhibitor 
concentrations relatively to the Km and Vmax values (Table I). For PPE, 𝐾!!"" remain 
constant and 𝑉!"#!"" decreases comparatively to Vmax, while for HNE, 𝐾!!"" and 𝑉!"#!"" 
decrease comparatively to Km and Vmax, respectively. A possible explanation for the 
irregular behaviour might stand in the peptide structure. Pep4 contains four cysteine 
residues that might form intramolecular and/or intermolecular disulfide bridges, leading 
potentially to some form of oligomerization of the peptide in solution. The potential 
formation of small polypeptides via disulfide bridges may induce differential inhibitory 
activity of this peptide towards elastase, which is reflected in the obtained kinetic 
parameters. This hypothesis was tested performing a kinetic assay of PPE inhibition by 
Pep4 (8 µM) in presence and absence of a reducing agent (DL-Dithiothreitol, 1-5 mM). 
However, the Michaelis-Menten plot revealed no significant differences between Pep4 
and Pep4+DTT hyperbolic curves (data not shown). Consequently, no alteration of the 
kinetic parameters, 𝐾!!"" and 𝑉!"#!"", were observed when Pep4 with and without DTT 
were used as elastase inhibitor (Figure 4). A mutated peptide (Pep4M) where the 
cysteine residues were replaced by the methionine residues was also used to eliminate 
the possibility of occurring disulfide bridges intra and inter-residues, which might alter 
the behaviour of the peptide in solution. Kinetic assays using Pep4M as inhibitor and 
PPE and HNE as enzyme have been performed (Figure 5 and Table II). In this assays, a 
similar behaviour to Pep4 has been obtained for Pep4M. No linear relation was 
observed between the inhibitor concentration and the attained kinetic parameters. As in 
the previous peptide, for PPE, 𝐾!!"" remain almost constant (except for the [I] = 2 µM 
assay) and 𝑉!"#!"" decreases comparatively to Vmax, while for HNE, 𝐾!!"" and 𝑉!"#!"" 
decrease comparatively to Km and Vmax, respectively. Kinetic studies on PPE using 
these inhibitor-peptides and different enzyme concentrations, substrate concentration 
range and also other buffer solution (200 µM phosphate buffer, pH 8.0) have been 
tested, although the same behaviour have been obtained. In order to have a control in 
these enzymatic assays, an elastase inhibitor selected from literature, elastatinal 54, was 
assessed with PPE and HNE. For this inhibitor a direct correlation between inhibitor 
concentration and the level of enzyme inhibition has been achieved, for both enzymes 
(PPE and HNE). Elastatinal behaves as a competitive inhibitor for both enzymes, PPE 
and HNE. The enzymes (E) and inhibitor (I) react according to the biomolecular and 
reversible mechanism described in Figure 6 a). Hence, the competitive inhibition 
constants, Kic, were deduced from equation 4 and the obtained Kic values collected in 
Table III. 
𝐾!!"" =   𝐾! 1+    𝑖𝐾!"           (4) 
PPE inhibition by Pep4 and Pep4M was analysed considering that elastase and the 
inhibitor-peptides follow a mixed inhibition mechanism, described in Figure 6 b). The 
analysis of direct linear plots (Figure 3 and 5) and the kinetic parameters resumed in 
Table I and II, for PPE inhibition by Pep4 and Pep4M, reveal that 𝐾!!"" remain constant 
and 𝑉!"#!"" decreases comparatively to Vmax and that alpha/alpha’ (α/α’) ratio is 
approximately one. Thus, PPE inhibition by both inhibitors-peptides is a particular case 
of the mixed inhibition, the non-competitive inhibition. In this inhibition type, the 
inhibition constants, Kic, and Kiu are similar and consequently Km is equal to 𝐾!!"". The 
inhibitions constants were determined from equation 5 and the respective values 
comprised in Table I and II. 
𝑉!"" =    𝑉1+    𝑖𝐾!"           (5) 
The inhibition constants, Kic and Kiu, increased with the inhibitor concentration, which 
it is not expected to occur. The inhibition kinetics of HNE by Pep4 and Pep4M was 
evaluated considering that enzyme and inhibitors follow an uncompetitive inhibition. 
According to the direct linear plots (Figure 3 b) and d) and Figure 5 b) and c)) and to the 
kinetic parameters included in Table I and II, for HNE inhibition by Pep4 and Pep4M, it 
is possible to state that 𝐾!!"" and 𝑉!"#!"" decrease comparatively to Km and Vmax, 
respectively. The ratio !!""!!!"" is constant for all inhibitor concentrations and identical to !!"#!! . For this inhibition type, the inhibition constant, Kiu, was determined using 
equation 5 and the obtained values were included in Table I and II.  
The inhibition constant, Kiu, increase with the inhibitor concentration and as previously 
emphasized this situation might be due to the absence of a direct relation between the 
inhibitor concentration applied and the levels of elastase inhibition achieved. Therefore, 
to better elucidate the behaviour of both peptides as elastase (PPE and HNE) inhibitors, 
a plot comprising the Vmax/Km ratio versus the inhibitor concentration was drawn 
(Figure 7). In this plot, for all the enzyme and peptide combinations the obtained result 
was nearly a horizontal straight line. In the HNE assays, this was the expected 
behaviour once in the uncompetitive inhibition the ratio Vmax/Km should remain 
unchanged for all the inhibitor concentrations. In opposition, in the PPE assays a 
decreasing line was expected, once in the mixed inhibition type the ratio Vmax/Km might 
decrease with the inhibitor concentration. 
In a previous work we have reported that Pep4 and Pep4M behave as slow velocity 
substrates of elastase (PPE) that at low concentrations function as elastase inhibitors 19. 
Even so, comparing the inhibition constant, Kic, for PPE in presence of Pep4 (0.46-5.00
µM), Pep4M (0.54-1.67 µM) and elastatinal (5.2±2.9 and 5.8±1.8 µM), it is thus 
possible to state that at lower inhibitor-peptide concentrations (lower than 8 µM) 
comparable values of Kic can be achieved for these inhibitor-peptides relatively to 
elastatinal. Moreover, according to these studies Pep 4 and Pep4M behaved as mixed 
PPE inhibitors, which mean that both peptides bind to the free enzyme (E) to give an EI 
complex or to the enzyme-substrate complex (ES) to give a complex ESI 55. In this 
particular case, as the α/α’ ratio is approximately one, these inhibitors bind in equal 
proportion both to the free enzyme and to the enzyme-substrate complex. However, 
these peptides behaved as uncompetitive HNE inhibitors, which means that these 
inhibitors only bind to the enzyme-substrate complex (ES) and do not to bind to the free 
enzyme (E). The current study revealed that for these elastase inhibitor-peptides, Pep 4 
and Pep4M, the PPE does not seems an appropriate enzymatic model for HNE, once no 
similar behaviour was observed for both enzymes in presence of these peptides. 
 
ROS Effect on Elastase Activity 
In humans, the endogenous antiproteases are known to be inactivated from stimulated 
neutrophils 26. For instance, alpha-1 Proteinase Inhibitor (α1-PI) an endogenous elastase 
inhibitor responsible for 90% of elastase inhibition in human serum, has been reported 
to be inactivated by leukocyte derived oxidants, including superoxide (O2•-) 56, 
hydrogen peroxide (H2O2) 27, 56, hypochlorous acid (HClO) 27, 57, 58 and hydroxyl radical 
(HO•) 59. 
Huang and co-workers 26 have reported a family of trifluoromethyl ketone elastase 
inhibitors, which resist superoxide, hypochlorous acid, hydrogen peroxide, hydroxyl 
radical and peroxinitrite mediated degradation. They have determined the stability of 
each inhibitor in the presence of superoxide, hypochlorous acid, hydrogen peroxide, 
hydroxyl radical and peroxinitrite, performing an incubation of two hours at 37ºC and 
then measuring the elastase activity, for one hour, in presence of the inhibitor-oxidant 
mixture. Wasil and co-works 27 have performed a similar study but they have added 
albumin to the inhibitor-oxidant mixture, which reveal to have a striking protective 
effect on the inhibitor. Both studies seemed relevant and of major importance, thus we 
have extended these studies to our current work. Therefore, Pep4, Pep4M and elastatinal 
(20 µM) were incubated with hydrogen peroxide (H2O2, 100 mM), hypochlorous acid 
(HClO, 100 µM), peroxinitrite (ONOO-, 500 µM) and superoxide (O2•-, 400 µM) and 
elastase (PPE) activity measured (Figure 8). The inhibitors concentration tested in this 
assay does not correspond to the concentration that mostly inhibits PPE. It has been 
used the same concentration for all inhibitors in order to establish a comparative study. 
In Figure 8 c) elastatinal reveals a considerable decrease in its inhibitory capacity 
towards elastase, due to the presence of ROS. When O2•-, HClO, H2O2 and ONOO-, 
were used as oxidant the inhibitory activity of elastatinal decreased between 14.0 and 
39.3%. In presence of albumin (BSA), the inhibitory capacity of elastatinal increased 
slightly for H2O2, ONOO- and O2•- and increased considerably for HClO, almost 
nullifying this ROS effect. This data is in accordance with a previous study 27, in which 
was reported that the presence of albumin, in concentrations lower than physiological 
concentrations, was able to completely inhibit inactivation of α1-PI by HClO. 
Presumably, albumin reacts with HClO and preferentially scavenges this radical. 
Therefore, albumin reveals substantial antioxidant activity by scavenging HClO 27.  
In Figure 8 b), Pep4M was also assayed with elastase in presence of the oxidant species 
H2O2, HClO, ONOO- and O2•-, revelling an unchangeable inhibitory behaviour in 
presence of these oxidants, with the exception of the peroxynitrite assay. In this 
particular case, the reduction of Pep4M inhibitory activity might be straightly related 
with the oxidation methionine residues (to methionine sulfoxide) at its catalytic centre, 
rendering to this peptide a decrement in its activity or even inactivation, in resemblance 
to what occur to α1-PI 57, 58, 60-62, SLPI 63, 64 and α2-macroglobulin 65, 66 in presence of 
reactive oxygen species. When albumin is added to the reaction mixture, the inhibitory 
capacity increases considerably to values lower than those found in the inhibitor assay 
(approximately 80%). Thus, albumin in this case protects the inhibitor-peptide (Pep4M) 
from ROS inactivation but also increases its inhibitory activity.  
The same study was performed for Pep4 (Figure 8 a)), revealing that the presence of 
O2•-decreased his inhibitory activity and increased when albumin is added to the 
reaction mixture, similarly to what has been shown in Pep4M study. Although, when 
H2O2, HClO and ONOO- were used as oxidants, the inhibitory capacity of Pep4 
increased, instead of decreasing, as it has occurred for the other two inhibitors (Pep4M 
and elastatinal). The addition of albumin to the reaction medium increased even more 
the inhibitory activity of Pep4, especially when H2O2, and ONOO- were used as 
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oxidants. In the case of radical HClO, the presence of albumin decreased slightly the 
inhibitory activity of Pep4.  
A possible explanation for these results might stand in the structural differences 
between these two inhibitor-peptides, Pep4 and Pep4M. Pep4M comprise four 
methionine residues, while Pep4 contains four cysteine residues that provide exposed 
free sulfhydryl groups (SH) that are very reactive and potential targets for radical attack. 
With respect to proteins, the thiol group of cysteinyl side chains is susceptible to a 
number of oxidative modifications, for instance, the formation of inter- or 
intramolecular disulfides between protein thiols (protein (P)-S-S-P) or between protein 
thiols and low-molecular-weight thiols such as glutathione (P-S-SG), the oxidation to 
sulfenic (P-SOH), sulfinic (P-SO2H), and sulfonic (P-SO3H) acid and S-nitrosylation 
(P-S-NO). These modifications can alter the function of numerous proteins that contain 
cysteines of structural importance, within their catalytic centers or as part of protein-
protein interaction interfaces 67-70. 
Thus, the H2O2 (or other ROS) attack to the thiol side chain (-SH) of cysteine residues 
in Pep4, might involve the formation of dissulphide bridges (S-S) or the –SH groups 
might be oxidized to sulphenic acid (-SOH) and this can be further oxidized to sulphinic 
acid (-SO2H) or sulphonic acid (-SO3H) 69. This structural modification might 
contribute to the increase of Pep4 inhibitory activity towards elastase comparatively to 
Pep4M, in this study. 
In addition, to better understand the albumin (BSA) effect on the system elastase-
inhibitor-peptide-ROS, some alterations have been introduced into the previous assay. 
The elastase enzymatic assay was performed in presence of Pep4M, Pep4M+H2O2, 
Pep4M+H2O2+BSA, Pep4+BSA, H2O2+BSA, H2O2 and BSA, as shown in Figure 9. In 
the current assay, elastase activity decreases 13.1%, 20.4% and 36.5% for Pep4M, 
Pep4M+H2O2 and Pep4M+H2O2+BSA, respectively. These results are in accordance 
with the results shown in Figure 8 b), for Pep4M in the  
presence of H2O2. When H2O2, Pep4M+BSA, BSA and H2O2+BSA were tested, the 
elastase activity decreased 24.0, 34.6, 35.2 and 39.7%, respectively. Higher elastase 
inhibition was achieved when H2O2+BSA (60.3%) is used, comparatively to 
Pep4M+BSA (65.4%) and BSA (64.8%). These results emphasized the fact that during 
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the incubation of BSA with H2O2, an alteration might occur in BSA. To visualize these 
potential modification two techniques were used, mass spectrometry (MS) and SDS-
PAGE electrophoresis. Solutions of BSA (50 mg/mL) with H2O2 (100 mM) were 
incubated during two and twenty-two hours at room temperature. These solutions were 
prepared in 20% methanol and further introduced in a mass spectrometer (Thermo 
Electron Corporation Instrument, model Finnigan LXQ, Waltham, MA, US). The 
referred equipment has an upper detection limit of 2000 m/z and within this range, only 
small fragments lower than 500 m/z have been detected (data not shown). These 
fragments could in fact correspond to peptides formed by three to four amino acids 
residues resulting from BSA degradation by H2O2, although we do not attribute them 
the responsibility for the decrease on elastase activity in this assay. Therefore, another 
technique has been used to study the possible modification in BSA. Solutions of BSA 
(0.125 - 2.0 mg/mL) and H2O2 (0.25 - 4.0 mM) were prepared and samples of BSA and 
BSA+H2O2, were incubated for two and twenty-two hours at room temperature and then 
loaded into 4% stacking gel and further separated in 8% resolving gel (Figure 10). 
Analysing these gels it was possible to state that no difference has been observed 
between the oxidant mixture BSA+H2O2 incubated for two or twenty-two hours and the 
correspondent control of BSA. Moreover, it was performed another assay using a 10% 
resolving gel instead of 8% and using the lowest BSA and H2O2 concentrations in the 
oxidant mixture (Figure 11). With this assay we intent to visualize whether some low 
molecular degradation products were formed during the incubation period of BSA with 
H2O2. As in the previous gel, no differences were observed between the BSA samples 
and the respective oxidant mixtures. Therefore, no experimental explanation has been 
found for the fact that the presence of BSA enhances the inhibitory activity of the 
selected inhibitor-peptides. We envisage that the inhibitory capacity of the studied 
peptides, Pep4 and Pep4M, might be enhance when in close contact with chronic wound 
exudate, due to the presence of albumin in wound medium. Moreover, the peptide 
concentrations tested in this assay (20 µM) is far from being the optimal concentration 
for each peptide to inhibit elastase. Thus, improved results are expected if 1 µM of Pep4 
or 4 µM Pep4M 19 were used, instead of 20 µM. Therefore, this study demonstrates that 
the selected peptides are optimal candidates to be applied in wound dressing 
applications. 
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Elastase Activity in presence of HA Hydrogel Formulations 
Hyaluronic acid is a naturally occurring polymer, non-immunogenic, non-adhesive 
glycosaminoglycan that plays a prominent role in various wound-healing processes, 
such as angiogenesis 71. Hyaluronic acid promotes early inflammation, which is critical 
for initiating wound healing, but then moderates later stages of this process, allowing 
matrix stabilization and reduction of long-term inflammation 71. Furthermore, 
environments around human tissues involved in regeneration and wound healing are 
enriched with HA 71. This cumulative evidence suggests that HA is an ideal candidate 
material for modulating wound healing. Therefore, HA hydrogels were used herein as 
wound dressings to enclose the inhibitors Pep4, Pep4M and elastatinal and further 
assayed their inhibitory capacity towards elastase (PPE and HNE). The Pep4, Pep4M 
and elastatinal concentrations used in the PPE assay were 1, 4 and 64 µM, while in the 
HNE assay were 32, 1 and 64 µM, respectively. These concentrations correspond to the 
inhibitor concentrations that highly contribute to the decrease on elastase activity. To 
assess the ability of the HA-inhibitor (Pep4, Pep4M and elastatinal) hydrogels to lower 
elastase activity, HA hydrogels with and without inhibitor were placed in a solution of 
elastase at physiological levels (36 mUnits/mL of elastase in chronic wounds) 46. The 
elastase activity present in the solution removed from the HA-inhibitor hydrogels were 
then compared with the activity of the solution from the HA without inhibitor (Figure 
12). All HA hydrogel formulations containing inhibitor (Pep4, Pep4M or elastatinal) 
were found to inhibit elastase (PPE and HNE) activity. In the PPE assays, Pep4 and 
Pep4M induced an elastase activity decrease of 34.6 and 37.1%, respectively. In the 
HNE assay, these peptides promoted a more considerable reduction on elastase activity, 
67.9% for Pep4 and 72.5% for Pep4M. Elastatinal achieves, in both assays, the higher 
elastase inhibition, with inhibition levels of 97.6 and 83.1% in the PPE and HNE assay, 
respectively. In the current study is shown a pattern, for both assays (PPE and HNE) the 
elastase inhibitory capacity obeys to an order: Pep4<Pep4M<Elastatinal.  
The HA films prepared for this assays were characterized in terms of water content and 
thickness. The water content of the HA hydrogels was determine as previously 
described, using equation 3. The water content average for the prepared HA hydrogels 
was 97.86±0.09%. The thickness of the HA films was determined using a micrometer 
and the average thickness of the prepared films was 29±4 µm.  
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 CONCLUSIONS 
In conclusion, the peptide fragments (Pep4: KRCCPDTCGIKCL and Pep4M: 
KRMMPDTMGIKML) selected from the endogenous elastase inhibitor secretory 
leucocyte protease inhibitor (SLPI), revealed to be moderate elastase inhibitors. 
According to the kinetic studies performed for HNE and PPE, these peptides behave as 
uncompetitive and non-competitive inhibitors of elastase, respectively. The studies on 
the influence of reactive oxygen species (H2O2, HClO, ONOO- and O2•-) and albumin 
(at physiological concentrations) in the inhibitory activity of Pep4 and Pep4M towards 
elastase revealed unexpected results. It was observed an increase in Pep4 inhibitory 
activity relatively to elastase when in presence of ROS. The incorporation of albumin 
(BSA) in the oxidant mixture also enhances the inhibitory capacity of both Pep4 and 
Pep4M towards elastase. The effect of albumin in the inhibitor peptide-oxidant mixture 
still remains unclear, however, it has been observed that ROS in the presence or absence 
of albumin do not influence negatively the inhibitory activity of the peptides towards 
PPE, in opposition to what occur with elastatinal. These results disclose an advantage of 
these peptides as elastase inhibitors for in vivo applications, once the presence of 
elevated levels of oxidant species are expected to occur under inflammatory conditions. 
Hyaluronic acid (HA) or hyaluron has gained much attention due to its prominent role 
in wound healing as well as its natural biodegradability. HA based hydrogels are 
designated by some authors as biomaterials that heal, because these biomimetic 
materials are designed to promote natural healing and regeneration 17. Thus, the HA 
hydrogels were chosen as our based material to incorporate the inhibitor-peptides and 
the resulting formulations evaluated as potential drug delivery system. These 
biomimetic materials were assessed in presence of HNE and PPE, at physiological 
concentrations (36 mUnits/mL of protease in chronic wounds) 46 and these formulations 
have induced a significant decrease in the elastase activity. 
According to Wiegand and co-workers, elastase concentration was found to be 10-times 
higher in chronic than in acute wound fluids (2,480.01 ng/mg and 245.85 ng/mg, 
respectively) 72. These finds emphasized the fact that no complete elastase inhibition is 
needed for the wound healing progress. Therefore, the inhibitor-peptides reported herein 
that have revealed moderated elastase inhibition, represent potential candidates for 
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wound dressing applications. The incorporation of these inhibitor-peptides (Pep4 and 
Pep4M) at very low concentrations (less cost) in HA hydrogel films, which promote 
natural wound healing and regeneration, might be taken in consideration for future 
therapeutic applications. 
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TABLES 
 
Table I Apparent kinetic parameters, Michaelis-Menten constant (Km), maximum enzyme velocity (Vmax) 
and inhibition dissociation constants (Kic and Kiu) for Human Neutrophil Elastase (HNE) and Porcine 
Pancreatic Elastase (PPE) in presence of different concentrations of inhibitor-peptide Pep4. 
 Table II Apparent kinetic parameters, Michaelis-Menten constant (Km), maximum enzyme velocity 
(Vmax) and inhibition dissociation constants (Kic and Kiu) for Human Neutrophil Elastase (HNE) and 
Porcine Pancreatic Elastase (PPE) in presence of different concentrations of inhibitor-peptide Pep4M. 
 
Table III Inhibition dissociation constant (Kic) for Porcine Pancreatic Elastase (PPE) and Human 
Neutrophil Elastase (HNE) in presence of elastatinal. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURES 
 
FIGURE 1 Image of a hyaluronic acid (HA) hydrogel film. HA hydrogel films were prepared 
by autocrosslinking as previously reported by Burns and co-workers 44. 
 
FIGURE 2 Schematic representation of the N-terminal domain of SLPI and its disulfide 
connectivities. Disulfide bonds are displayed by solid lines while inter-main-chain hydrogen 
bonds are represented by dashed lines. The Pep4 sequence is highlighted with grey circles. The 
current image was adapted from Grütter and Bode X-ray study on SLPI structure 50. 
 
FIGURE 3 Reaction velocity plots for porcine pancreatic elastase (0.3 units/mL) and human 
neutrophil elastase (0.5 units/mL) in presence of Pep4. Kinetic parameters were determined by 
nonlinear regression analysis, Michaelis-Menten plot a) and c) and by linear regression studies, 
Direct Linear plot b) and d), for PPE and HNE respectively. In the Direct Linear plots the black 
lines correspond to the elastase enzymatic assay without inhibitor and the grey lines to the 
enzymatic assay performed in presence of Pep4 (1 µM and 32 µM of Pep4 in the PPE and HNE 
assay, respectively). The current assays were performed in triplicate. 
 
FIGURE 4	   Influence of DTT on the kinetic parameters, Km, (■) and Vmax, (■) of Porcine 
Pancreatic Elastase (PPE) in the presence of 8 µM of Pep4. Each data point represents the 
average of three independent determinations. 
 
FIGURE 5 Reaction velocity plots for porcine pancreatic elastase (0.3 units/mL) and human 
neutrophil elastase (0.5 units/mL) in presence of Pep4M. Kinetic parameters were determined 
by nonlinear regression analysis, Michaelis-Menten plot a) and c) and by linear regression 
studies, Direct Linear plot b) and d), for PPE and HNE respectively. In the Direct Linear plots 
the black lines correspond to the elastase enzymatic assay without inhibitor and the grey lines to 
the enzymatic assay performed in presence of Pep4M (4 µM and 1 µM of Pep4M in the PPE 
and HNE assay, respectively). The current assays were performed in triplicate. 
 
FIGURE 6 Schematic representation of the models for competitive inhibition a) and mixed 
inhibition b). Adapted from the reference 55. 
 
FIGURE 7	  Influence of inhibitor concentrations (Pep4 and Pep4M) on Vmax/Km ratio for the 
PPE a) and HNE b) reactions. The PPE and HNE assays were represented by triangles and 
squares, respectively, while the presence of Pep4 and Pep4M were represented by dark and light 
grey lines.	  
 
FIGURE 8 Effect of hydrogen peroxide (H2O2), hypochlorous acid (HOCl), peroxinitrite 
(ONOO-) and superoxide anion (O2•–) on elastase inhibitory activity of Pep4 a), Pep4M b) and 
elastatinal c). PPE activity was determined spectrophotometrically at 410 nm, using as substrate 
N-succinyl-Ala-Ala-Ala-p-nitroanilide. These assays were performed in presence of inhibitor 
(■) with oxidante (■) with oxidante + albumin (■) treatment and without inhibitor (■). 
Experiments were performed under identical conditions with or without oxidant treatment. Data 
shown are the average of three independent measurements. 
 
FIGURE 9 Effect of hydrogen peroxide (H2O2) on elastase inhibitory activity of Pep4M. PPE 
activity was assayed spectrophotometrically at 410 nm using N-succinyl-Ala-Ala-Ala-p-
nitroanilide as substrate, in presence of Pep4M in different oxidative mixtures: Pep4M+ H2O2; 
Pep4M+ H2O2+BSA; Pep4M+BSA; H2O2+BSA; H2O2 and BSA. Data shown are the mean ± 
SD of triplicate determinations. 
 
FIGURE 10 Visualization of potential reaction products from the reaction albumin + hydrogen 
peroxide by SDS-PAGE. Electrophorese gels were prepared using 4% stacking gels and 8% 
resolving gels. Gel revelation was performed with Coomassie blue. 
Lane 1: Protein markers; lane 2: BSA (0.125 mg/mL)+H2O2 (0.25 mM), incubation time = 22 
hours; lane 3: BSA (0.125 mg/mL)+H2O2 (0.25 mM), incubation time = 2 hours; lane 4: BSA 
(0.125 mg/mL); lane 5: BSA (0.25 mg/mL)+H2O2 (0.50 mM), incubation time = 22 hours; lane 
6: BSA (0.25 mg/mL)+H2O2 (0.50 mM), incubation time = 2 hours; lane 7: BSA (0.25 mg/mL); 
lane 8: protein marker; lane 9: BSA (0.50 mg/mL)+H2O2 (1.0 mM), incubation time = 22 hours; 
lane 10: BSA (0.50 mg/mL)+H2O2 (1.0 mM), incubation time = 2 hours; lane 11: BSA (0.50 
mg/mL); lane 12: BSA (1.0 mg/mL)+H2O2 (2.0 mM), incubation time = 22 hours; lane 13: BSA 
(1.0 mg/mL)+ H2O2(2.0 mM), incubation time = 2 hours; lane 14: BSA (1.0 mg/mL); lane 15: 
BSA (2.0 mg/mL)+H2O2 (4.0 mM), incubation time = 22 hours; lane 16: BSA (2.0 
mg/mL)+H2O2 (4.0 mM), incubation time = 2 hours; lane 17: BSA (2.0 mg/mL). 
 
FIGURE 11 Visualization of potential reaction products from the reaction albumin + hydrogen 
peroxide by SDS-PAGE. Electrophorese gels were prepared using 4% stacking gels and 10% 
resolving gels. Gel revelation was performed with Coomassie blue. 
Lane 1: Protein markers; lane 2: BSA (0.125 mg/mL)+H2O2 (0.25 mg/mL), incubation time = 
22 hours; lane 3: BSA (0.125 mg/mL)+H2O2 (0.25 mM), incubation time = 2 hours; lane 4: 
BSA (0.125 mg/mL); lane 5: BSA (0.25 mM)+H2O2 (0.50 mg), incubation time = 22 hours; lane 
6: BSA (0.25 mg/mL)+H2O2 (0.50 mM), incubation time = 2 hours; lane 7: BSA (0.25 mg/mL). 
 
FIGURE 12 Evaluation of the effect of HA hydrogel formulations on elastase activity. The 
measurement of elastase activity at physiological conditions (36 mU/mL PPE and HNE) was 
performed spectrophotometrically by monitoring the release of p-nitroaniline at 410 nm from 
the enzymatic hydrolysis of the substrate N-succinyl-Ala-Ala-Ala-p-nitroanilide (4.4 mM) and 
MeOSuccinyl-Ala-Ala-Pro-Val-p-nitroanilide (3.0 mM), respectively. The HA hydrogel 
formations tested in the PPE (■) and HNE (■) assays, contain Pep4 (1 and 32 µM), Pep4M (4 
and 1 µM) and elastatinal (64 µM), respectively. Data shown represent the mean of three assays 
± SD. 
 
